Scientists Identify Reasons for Excluding Women from

Main Reasons for Excluding Women from Experiments

In 2026, a study conducted by scientists at the U.S. National Institutes of Health identified key reasons why women are often excluded from scientific experiments. One major factor is the difference in stress response and physiological markers between men and women, complicating data standardization.

The study found that about 60% of clinical trials in pharmacology and psychology still primarily target male participants, leading to underrepresentation of women and skewed results that affect treatment efficacy.

Methodological Challenges in Study Design

One methodological challenge is the need to account for women’s hormonal cycles, which requires additional time and resources. For example, studies involving women must observe at least two menstrual cycles, extending experiment durations by 30-40% compared to similar tests on men.

As a result, many research organizations, including the European Medicines Agency, prefer excluding women from pilot trials to reduce costs and speed up the process. However, this creates gaps in knowledge about the female body.

Impact on Medical and Pharmaceutical Outcomes

The lack of adequate female representation in studies leads to less effective and sometimes hazardous medications for women. According to the World Health Organization, around 35% of drugs approved in the past five years have unaccounted side effects in women.

This negatively affects health and increases treatment costs. For example, extra hospitalizations of women due to adverse reactions cost the U.S. healthcare system approximately $1.2 billion annually.

The Role of Institutions and Public Policy

In 2021, the U.S. National Institutes of Health introduced mandatory requirements to include women in clinical trials, but enforcement remains inconsistent. Russia and the European Union only began implementing similar rules in 2024, with little improvement so far.

Some pharmaceutical companies like Pfizer and Novartis are actively developing programs to involve more women in research, allocating up to 15% additional budget for this. This marks a first step toward correcting the imbalance, though systemic changes will take time.

The Need for Further Research

Scientists emphasize that fully understanding the differences in male and female biological responses requires long-term, large-scale studies with at least 50% female participants. This approach will account for biological and social factors affecting health.

Additionally, international organizations such as the World Medical Alliance are developing standards for including women in research, expected to be adopted by 2028. This will help improve scientific data quality and medical practice.

Conclusion: Systemic and methodological barriers exclude women from scientific experiments, lowering the quality of medicine and demanding urgent changes in research practices.